Associated Genetic Biomarkers
Malignant neoplasms most frequently harbor alterations in TP53, CDKN2A, NF1, CDKN2B, and SMARCA4 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in malignant neoplasm .
There is 1 clinical trial for malignant neoplasm, of which 0 are open and 1 is completed or closed. Of the trial that contains malignant neoplasm as an inclusion criterion, 1 is phase 2 (0 open).
ALK is the most frequent gene inclusion criterion for malignant neoplasm clinical trials .
Significant Genes in Malignant Neoplasm
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.